CA-GSD/ANANDA
23.3.2021 16:02:07 CET | Business Wire | Press release
POSITIVE ALL THE WAY , an award-winning documentary about the Paralympics is now available internationally through Ananda Media. The short documentary, produced by The Foundation for Global Sports Development (GSD) and Sidewinder Films, won “Best Documentary” at the Together! 2020 Disability Film Festival .
With personal interviews and captivating footage, POSITIVE ALL THE WAY celebrates the power of adaptive sport to ignite the human spirit. The film chronicles the growth of the Paralympics under the leadership of Sir Philip Craven, who served as the President of the International Paralympic Committee from 2001 through 2017. Staying true to the integrity of sport and his personal principles, Sir Philip led the sports organization through moments of crisis – such as funding shortfalls and the 2016 Russian doping scandal - while positioning the Paralympics as a leading sports organization.
"Ever since I first met Steven Ungerleider and David Ulich in 2011, I very quickly realized that the true spirit of sport is embodied in everything that The Foundation for Global Sports Development and Sidewinder Films undertakes,” said Sir Philip Craven, who is featured in the film. “In my work with the International Paralympic Committee, I tried to follow that principle and to also follow very closely the vision of the IPC which was ’to enable Para athletes to achieve sporting excellence and inspire and excite the world.’ This is what I believe Sidewinder Films portrays in POSITIVE ALL THE WAY , and I am so pleased that they have partnered with Ananda Media in order that many more people can experience the true spirit of sport!”
"The Paralympic movement reaches across the globe and plays a remarkable role in promoting inclusion worldwide,” said David Ulich, director and producer of the film. “We are delighted to partner with Ananda Media to bring POSITIVE ALL THE WAY to international audiences who can join this movement.”
Dr. Steven Ungerleider, director and producer of POSITIVE ALL THE WAY, agreed. “Sport has the power to change the world, and we are passionate about telling those stories through film. Working with Ananda Media is a perfect fit, and we are honored to have our documentary featured alongside other compelling sports films.”
Ananda Media is a French-based distributor of adventure sports, travel, and healthy lifestyle content. Much of their content, including POSITIVE ALL THE WAY , is available on-demand for worldwide audiences. Visit http://anandamedia.net to learn more.
About Ananda Media
Ananda Media is a producer and distributor of action sports and adventure travel programming for television and digital media. We pride ourselves on working with the top independent film-makers, and TV Channels in order to ensure that our content offering is both unparalleled and broadcast, streamed or downloaded to millions around the world.
More info: http://anandamedia.net
About The Foundation for Global Sports Development and Sidewinder Films
The Foundation for Global Sports Development, established in 1996, was born out of a desire to promote and protect the best parts of sport. Guided by its original mission, the foundation delivers and supports initiatives that promote accessible, fair, and abuse-free sport for youth. The foundation achieves this objective through grants, awards, educational projects, and filmmaking. In 2015, the foundation launched its media company, Sidewinder Films, to inspire and educate audiences through films that shed light on the remarkable, untold stories that celebrate the sport of life. Visit www.globalsportsdevelopment.org and www.sidewinderfilms.org to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005297/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom